Recruiting Spinal Muscular Atrophy Studies in Minneapolis
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab...
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumor...
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation....
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participan...
About Spinal Muscular Atrophy Clinical Trials in Minneapolis
Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder that causes loss of motor neurons, leading to progressive muscle weakness and atrophy. It is the leading genetic cause of infant death. Revolutionary gene therapies and SMN-enhancing drugs have transformed treatment.
There are currently 4 spinal muscular atrophy clinical trials recruiting participants in Minneapolis, MINNESOTA. These studies are seeking a combined 1,097 participants. Research is being sponsored by Bristol-Myers Squibb, Greg Durm, MD, Mirati Therapeutics Inc. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Spinal Muscular Atrophy Clinical Trials in Minneapolis — FAQ
Are there spinal muscular atrophy clinical trials in Minneapolis?
Yes, there are 4 spinal muscular atrophy clinical trials currently recruiting in Minneapolis, MINNESOTA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Minneapolis?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you about next steps.
Are clinical trials in Minneapolis free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Minneapolis studies also compensate for your time and travel.
What spinal muscular atrophy treatments are being tested?
The 4 active trials in Minneapolis are testing new therapies including novel drugs, biologics, and treatment approaches for spinal muscular atrophy.
Data updated March 2, 2026 from ClinicalTrials.gov